Generation and cryopreservation of clinical grade Wilms' tumor 1 mRNA-loaded dendritic cell vaccines for cancer immunotherapy
Faculty of Medicine and Health Sciences
Methods in molecular biology. - Totowa, N.J., 1984, currens
, p. 27-35
University of Antwerp
First described in the seventies, dendritic cells (DC) are currently the subject of intense investigation to exploit their unique antigen-presenting and immunoregulatory capacities. In cancer, DC show promise to elicit or amplify immune responses directed against cancer cells by activating natural killer (NK) cells and tumor antigen-specific T cells. Wilms tumor 1 (WT1) protein is a tumor-associated antigen that is expressed in a majority of cancer types and has been designated as an antigen of major interest to be targeted in clinical cancer immunotherapy trials. In this chapter, we describe the generation, cryopreservation and thawing of clinical grade autologous monocyte-derived DC vaccines that are loaded with WT1 by messenger RNA (mRNA) electroporation. This in-house developed transfection method gives rise to presentation of multiple antigen epitopes and can be used for all patients without restriction of human leukocyte antigen (HLA) type.